Roche ’s Ocrevus receives TGA approval for RMS and PPMS treatment in Australia

The Australian Therapeutic Goods Administration (TGA) has granted approval for Roche ’s Ocrevus (ocrelizumab) for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news